Treating Thyroid Associated Ophthalmopathy in Pediatric Patients

Area of Science:

• Endocrinology
• Ophthalmology
• Pharmacology

Background:

• Thyroid-associated ophthalmopathy (TAO) is an inflammatory condition affecting eye and orbital tissues, often linked to Graves' disease.
• TAO impacts children's quality of life, with up to one-third of pediatric Graves' disease patients potentially affected.
• Teprotumumab, an IGF-1R inhibitor, is FDA-approved for TAO but lacks established pediatric safety data.

Purpose of the Study:

• To evaluate the safety and efficacy of teprotumumab for pediatric patients with TAO.
• To assess potential developmental toxicity associated with teprotumumab targeting the insulin-like growth factor-1 receptor (IGF-1R).

Main Methods:

• Pharmacology review of repeated-dose toxicity studies in juvenile monkeys.
• Assessment of teprotumumab's effects on growth, thymus, spleen, and bone development.

Main Results:

• No No Observed Adverse Effect Level (NOAEL) was identified in juvenile monkeys.
• Teprotumumab negatively impacted growth, thymus, spleen, and bone development, with younger animals showing increased sensitivity.
• Hearing impairment was identified as an additional risk for pediatric use.

Conclusions:

• Teprotumumab's developmental toxicity in juvenile animal models raises significant safety concerns for pediatric TAO treatment.
• The drug's impact on growth and potential for hearing impairment necessitates caution and further research before pediatric use.
• Empirical use of teprotumumab in children is not recommended; further development is needed to establish pediatric safety and efficacy.